Quantum Biopharma Ltd. (NASDAQ:QNTM – Get Free Report) was down 4.8% during mid-day trading on Monday . The company traded as low as $4.20 and last traded at $4.40. Approximately 38,219 shares were traded during trading, a decline of 97% from the average daily volume of 1,134,356 shares. The stock had previously closed at $4.62.
Quantum Biopharma Trading Down 1.1 %
The business’s 50-day moving average price is $5.52. The company has a market cap of $8.71 million, a PE ratio of -0.29 and a beta of 0.37.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Quantum Biopharma stock. Virtu Financial LLC acquired a new stake in Quantum Biopharma Ltd. (NASDAQ:QNTM – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 11,428 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned about 0.60% of Quantum Biopharma at the end of the most recent reporting period. 1.24% of the stock is currently owned by institutional investors and hedge funds.
About Quantum Biopharma
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
See Also
- Five stocks we like better than Quantum Biopharma
- How to trade using analyst ratings
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- How to Capture the Benefits of Dividend Increases
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Which Wall Street Analysts are the Most Accurate?
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.